Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OGD's Sporn moving to Abbott

This article was originally published in The Tan Sheet

Executive Summary

FDA Office of Generic Drugs Director Douglas Sporn is joining Abbott Labs as divisional VP, corporate regulatory affairs March 1. OGD Deputy Director Gary Buehler will serve as acting director. Sporn has been with CDER since 1990 and has led the generics division since 1996. In his 26 years at the agency, Sporn also has served as deputy director of the Office of Pharmaceutical Sciences and held positions in the commissioner's office and the Center for Devices & Radiological Health. Sporn is the second FDAer to move to Abbott in the last three months; former CBER Deputy Director Michael Beatrice joined the firm as VP-corporate regulatory and quality science in November. Sporn reports to Beatrice in his new post

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel